| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 224 4 |
| Ultima descărcare din IBN: 2023-09-13 15:31 |
 SM ISO690:2012GUNTHER, Gunar, , , ALEXANDRU, Sofia, , , BARBUŢĂ, Raisa, KRUDU, V., CERNENCO, Ilie, DUBCEAC, Vera. Multidrug-resistant tuberculosis in Europe, 2010-2011. In: Emerging Infectious Diseases, 2015, vol. 21, nr. 3, pp. 409-416. ISSN 1080-6040. DOI: https://doi.org/10.3201/eid2103.141343 |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
  Emerging Infectious Diseases |
|
| Volumul 21, Numărul 3 / 2015 / ISSN 1080-6040 /ISSNe 1080-6059 | |
|
|
| DOI:https://doi.org/10.3201/eid2103.141343 | |
| Pag. 409-416 | |
 Descarcă PDF |
|
| Rezumat | |
Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to >1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fuoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe. |
|
| Cuvinte-cheie adult, Antitubercular Agents, comorbidity, Cross-Sectional Studies, Europe, female, history, 21st Century, Humans, incidence, Male, Microbial Sensitivity Tests, middle aged, Mycobacterium tuberculosis, Population Surveillance, risk factors, tuberculosis, Multidrug-Resistant |
|
|
Dublin Core Export
<?xml version='1.0' encoding='utf-8'?> <oai_dc:dc xmlns:dc='http://purl.org/dc/elements/1.1/' xmlns:oai_dc='http://www.openarchives.org/OAI/2.0/oai_dc/' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd'> <dc:creator>Gunther, G.</dc:creator> <dc:creator>Gunther, G.</dc:creator> <dc:creator>Alexandru, S.</dc:creator> <dc:creator>Alexandru, S.</dc:creator> <dc:creator>Barbuţă, R.</dc:creator> <dc:creator>Crudu, V.N.</dc:creator> <dc:creator>Cernenco, I.</dc:creator> <dc:creator>Dubceac, V.</dc:creator> <dc:date>2015-03-01</dc:date> <dc:description xml:lang='en'><p>Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to >1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fuoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.</p></dc:description> <dc:identifier>10.3201/eid2103.141343</dc:identifier> <dc:source>Emerging Infectious Diseases (3) 409-416</dc:source> <dc:subject>adult</dc:subject> <dc:subject>Antitubercular Agents</dc:subject> <dc:subject>comorbidity</dc:subject> <dc:subject>Cross-Sectional Studies</dc:subject> <dc:subject>Europe</dc:subject> <dc:subject>female</dc:subject> <dc:subject>history</dc:subject> <dc:subject>21st Century</dc:subject> <dc:subject>Humans</dc:subject> <dc:subject>incidence</dc:subject> <dc:subject>Male</dc:subject> <dc:subject>Microbial Sensitivity Tests</dc:subject> <dc:subject>middle aged</dc:subject> <dc:subject>Mycobacterium tuberculosis</dc:subject> <dc:subject>Population Surveillance</dc:subject> <dc:subject>risk factors</dc:subject> <dc:subject>tuberculosis</dc:subject> <dc:subject>Multidrug-Resistant</dc:subject> <dc:title>Multidrug-resistant tuberculosis in Europe, 2010-2011</dc:title> <dc:type>info:eu-repo/semantics/article</dc:type> </oai_dc:dc>
|
|
|
